导师姓名： 庄光磊 专业代码： 100214
性别： 男 专业名称： 肿瘤学
培养单位： 附属仁济医院 三级学科/
专业领域：
导师类型： 博士生导师 专业学位导师：
联系方式： zhuanglab@163.comhttps://www.ncbi.nlm.nih.gov/myncbi/1zSir8mXVIh50/bibliography/public/
邮编： 邮箱地址： zhuangguanglei@163.com

研究方向 (点击浏览详细信息)
肿瘤动态演进与靶向治疗

社会任职
中国城市科学研究会健康城市专业委员会委员
中国生理学会基质生物学专业委员会委员
上海市妇科肿瘤重点实验室副主任

科研项目 项目编号项目名称课题来源起止年月批准经费承担职责
** 肿瘤动态演进与靶向治疗 国家自然科学基金优青项目 2020-01~2022-12 120万元 课题负责人
** 去泛素化酶USP13促进MCL1稳定性和肿瘤发展的机制研究 国家自然科学基金面上项目 2017-01~2020-12 58万元 课题负责人
16QA** 肺癌的分子诊断和精准治疗研究 上海市青年科技启明星计划 2016-04~2019-03 40万元 课题负责人
2015 卵巢癌表观遗传治疗研究 上海高校**** 2015-07~2018-06 100万元 课题负责人
** 特异micoRNAs与Lin28B的相互调控促进黑色素瘤发展的机制研究 国家自然科学基金面上项目 2015-01~2018-12 78万元 课题负责人

学术论文 作者论文标题期刊名出版年卷期页码
Cai MC, Zhao X, Cao M, Ma P, Chen M, Wu J, Jia C, He C, Fu Y, Tan L, Xue X, Yu Z, Zhuang G. （通讯作者） T-cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment. J Pathol. 2020 251(2):147-159.
Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y, Yang Y, Diao L, Lin SH, Mills GB, Zhuang G （通讯作者）, Xue X, Han L. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun. 2020 In press.
Yin X, Bi R, Ma P, Zhang S, Zhang Y, Sun Y, Zhang Y, Jing Y, Yu M, Wang W, Tan L, Di W, Zhuang G （通讯作者）, Cai MC. Multiregion whole-genome sequencing depicts intratumour heterogeneity and punctuated evolution in ovarian clear cell carcinoma. J Med Genet 2019 jmedgenet-2019-106418.
Jing Y, Zhang Y, Zhu H, Zhang K, Cai MC, Ma P, Shen P, Zhang Z, Shao M, Wang J, Yu M, Yin X, Zhang M, Hu Y, Chen D, Di W, Wang X, Zhuang G. （通讯作者） Hybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer. Oncogene 2019 38(16):3047-3060.
Shi K, Yin X, Cai MC, Yan Y, Jia C, Ma P, Zhang S, Zhang Z, Gu Z, Zhang M, Di W, Zhuang G. （通讯作者） PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors. Elife 2019 8. pii: e44306.
Cai MC, Chen M, Ma P, Wu J, Lu H, Zhang S, Liu J, Zhao X, Zhuang G （通讯作者）, Yu Z, Fu Y. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer. Int J Cancer 2019 144(4):788-801.
Zhang S, Zhang M, Jing Y, Yin X, Ma P, Zhang Z, Wang X, Di W, Zhuang G. （通讯作者） Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nat Commun. 2018 9(1):215.
Shen P, Jing Y, Zhang R, Cai MC, Ma P, Chen H, Zhuang G. （通讯作者） Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics. Oncogene. 2018 37(22):3039-3044.
Lu H, Zhang S, Wu J, Chen M, Cai MC, Fu Y, Li W, Wang J, Zhao X, Yu Z, Ma P, Zhuang G. （通讯作者） Molecular targeted therapies elicit concurrent apoptotic and GSDME-dependent pyroptotic tumor cell death. Clin Cancer Res. 2018 pii: clincanres.1478.2018.
Jing Y, Zhang R, Ma P, Cai MC, Zhuang G （通讯作者）, Chen H. Prevalence and clonality of synchronous primary carcinomas in the bladder and prostate. J Pathol. 2018 244(1):5-10.
Zhang M, Zhuang G （共同第一作者）, Sun X, Shen Y, Wang W, Li Q, Di W. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer Diagn Pathol 2017 12(1):16.
Ma P, Fu Y, Cai MC, Yan Y, Jing Y, Zhang S, Chen M, Wu J, Shen Y, Zhu L, Chen HZ, Gao WQ, Wang M, Gu Z, Bivona TG, Zhao X, Zhuang G. （通讯作者） Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nat Commun. 2017 8(1):823.
Zhang Z, Peng H, Wang X, Yin X, Ma P, Jing Y, Cai MC, Liu J, Zhang M, Zhang S, Shi K, Gao WQ, Di W, Zhuang G. （通讯作者） Preclinical efficacy and molecular mechanism of targeting CDK7-dependent transcriptional addiction in ovarian cancer Mol Cancer Ther 2017 16(9):1739-1750.
Yin X, Jing Y, Cai MC, Ma P, Zhang Y, Xu C, Zhang M, Di W, Zhuang G. （通讯作者） Clonality, Heterogeneity, and Evolution of Synchronous Bilateral Ovarian Cancer. Cancer Res. 2017 77(23):6551-6561.
Zhu HH, Zhuang G （共同第一作者）, Gao WQ. A candidate gastric stem/progenitor cell marker revealed by genome-wide analysis J Pathol 2016 238(1):3-6.
Ma P, Fu Y, Chen M, Jing Y, Wu J, Li K, Shen Y, Gao JX, Wang M, Zhao X, Zhuang G. （通讯作者） Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway Theranostics 2016 6(8):1232-43.
Jing Y, Zhang Z, Ma P, An S, Shen Y, Zhu L, Zhuang G. （通讯作者） Concomitant BET and MAPK blockade for effective treatment of ovarian cancer Oncotarget 2016 7(3):2545-54.
Yin X, Wang X, Shen B, Jing Y, Li Q, Cai MC, Gu Z, Yang Q, Zhang Z, Liu J, Li H, Di W, Zhuang G. （通讯作者） A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis Sci Rep 2016 6:31079.
Zhang Z, Ma P, Jing Y, Yan Y, Cai MC, Zhang M, Zhang S, Peng H, Ji ZL, Di W, Gu Z, Gao WQ, Zhuang G. （通讯作者） BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1 Theranostics 2016 6(2):219-30.
Zhang S, Jing Y, Zhang M, Zhang Z, Ma P, Peng H, Shi K, Gao WQ, Zhuang G. （通讯作者） Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer Sci Rep 2015 5:16066.
Zhang Z, Zhang S, Ma P, Jing Y, Peng H, Gao WQ, Zhuang G. （通讯作者） Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit Carcinogenesis 2015 36(9):937-45.
Li X, Liu Y, Chen W, Fang Y, Xu H, Zhu HH, Chu M, Li W, Zhuang G （通讯作者）, Gao WQ. TOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer Oncotarget 2014 5(19):9498-513.
Brauer MJ, Zhuang G （共同第一作者）, Schmidt M, Yao J, Wu X, Kaminker JS, Jurinka SS, Kolumam G, Chung AS, Jubb A, Modrusan Z, Ozawa T, James CD, Phillips H, Haley B, Tam RN, Clermont AC, Cheng JH, Yang SX, Swain SM, Chen D, Scherer SJ, Koeppen H, Yeh RF, Yue P, Stephan JP, Hegde P, Ferrara N, Singh M, Bais C. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies Clin Cancer Res 2013 19(13):3681-92.
Zhuang G （共同第一作者）, Yu K, Jiang Z, Chung AS, Yao J, Ha C, Toy K, Soriano R, Haley B, Blackwood E, Sampath D, Bais C, Lill JR, Ferrara N. Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases Science Signaling 2013 6(271):ra25.
Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, Oeh J, Modrusan Z, Bais C, Sampath D, Ferrara N. Tumor-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway EMBO J 2012 31(17):3513-23.
Zhuang G （共同第一作者）, Song W, Amato K, Hwang Y, Lee K, Boothby M, Ye F, Guo Y, Shyr Y, Lin L, Carbone DP, Brantley-Sieders DM, Chen J. Effects of cancer-associated EPHA3 mutations on lung cancer J Natl Cancer Inst 2012 104(15):1183-98.
Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, Jackson D, Muraoka-Cook R, Arteaga C, Chen J. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy Cancer Res 2010 70(1):299-308.
Brantley-Sieders DM, Zhuang G （共同第一作者）, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, Chen J. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling J Clin Invest 2008 118(1):64-78.
Zhuang G, Hunter S, Hwang Y, Chen J. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation J Biol Chem 2007 282(4):2683-94.